To thisend, phenotyping patients with pericarditis and addressing such therapies tothose presenting with auto-inflammatory features (elevated C-reactive protein,sustained pericardial and systemic inflammation, multiple recurrences) is ofutmost importance to identify patients who might be more likely to benefit fromNLRP3 inflammasome/IL-1β pathway blockade. Here, IL1B is linked to pericarditis.